Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

The p53 breast cancer tissue biomarker in Indian women

Authors Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Published 11 August 2011 Volume 2011:3 Pages 71—78


Review by Single-blind

Peer reviewer comments 5

This paper has been retracted.
Vinayak W Patil1, Mukund B Tayade2, Sangeeta A Pingale1, Shubhangi M Dalvi1, Rajesh B Rajekar1, Hemkant M Deshmukh1, Shital D Patil1, Rajeev Singhai1
1Department of Biochemistry, 2Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India

Background: Combination chemotherapy is highly effective in locally advanced breast cancer. A negative expression of biomarker p53 indicates a higher chance of responding to this regimen. Patients' p53 status may be used as a biological cancer marker to identify those who would benefit from more aggressive treatments.
Aims: The role of p53 in modulating apoptosis has suggested that it may affect the efficacy of anticancer agents. p53 alterations in 80 patients with locally advanced breast cancer IIIB undergoing neoadjuvant chemotherapy were prospectively evaluated.
Materials and methods: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression, using immunohistochemistry and DNA sequencing.
Results: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of 25 patients who obtained a complete clinical response, only two were classified as p53-positive (P = 0.004, χ2). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, χ2).
Conclusion: Immunohistochemical (IHC) analysis has been shown to be a prognostic factor for patients with breast cancer in India. Paclitaxel is one of the most promising anticancer agents for the therapy of breast cancer, where it has also shown activity in tumors resistant to doxorubicin.

Keywords: breast cancer, doxorubicin, p53, paclitaxel, cancer tissue biomarkers, neoadjuvant chemotherapy, immunohistochemistry, infiltrating duct cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Breast Cancer: Targets and Therapy 2011, 3:27-33

Published Date: 19 April 2011

Cancer biomarker HER-2/neu in breast cancer in Indian women

Singhai R, Patil VW, Patil AV

Breast Cancer: Targets and Therapy 2011, 3:21-26

Published Date: 29 March 2011

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Breast Cancer: Targets and Therapy 2011, 3:9-19

Published Date: 16 March 2011

Readers of this article also read:

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells

Wang YY, Yang YX, Zhao R, Pan ST, Zhe H, He ZX, Duan W, Zhang X, Yang TX, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:993-1026

Published Date: 17 February 2015

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]

Della Pepa C, Banerjee S

OncoTargets and Therapy 2014, 7:1473-1474

Published Date: 20 August 2014

Advance care planning in stroke: influence of time on engagement in the process

Green T, Gandhi S, Kleissen T, Simon J, Raffin-Bouchal S, Ryckborst K

Patient Preference and Adherence 2014, 8:119-126

Published Date: 24 January 2014

Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule

Lee SG, Jeong JH, Lee KM, Jeong KH, Yang H, Kim M, Jung H, Lee S, Choi YW

International Journal of Nanomedicine 2014, 9:289-299

Published Date: 31 December 2013

Breast cancer causes and treatment: where are we going wrong?

Seymour CB, Mothersill C

Breast Cancer: Targets and Therapy 2013, 5:111-119

Published Date: 3 December 2013


Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF

International Journal of Nanomedicine 2012, 7:5107-5108

Published Date: 21 September 2012

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study

Olivieri E, Vecchiato C, Ignaccolo N, Mannu P, Castagna A, Aravagli L, Fontani V, Rinaldi S.

Neuropsychiatric Disease and Treatment 2011, 7:449-455

Published Date: 4 August 2011